Neurological Conditions

Parkinson's Disease Autonomic Dysfunction

PD Autonomic Dysfunction · G20

Autonomic dysfunction in Parkinson's disease is a non-motor symptom affecting 70-80% of patients, including orthostatic hypotension, constipation, urinary dysfunction, and sweating disorders.

2026-03-28

At a Glance

Autonomic dysfunction in Parkinson's disease (PD) results from alpha-synuclein accumulation in autonomic ganglia and brainstem nuclei. Orthostatic hypotension affects 30-40% of PD patients and is worsened by dopaminergic medications. Constipation is present in 60-80% and may precede motor symptoms by years. Urinary dysfunction (frequency, urgency, nocturia) affects 40-70%. MIBG myocardial scintigraphy shows reduced cardiac uptake, distinguishing PD from MSA. HRV analysis reveals reduced overall variability. Management includes fludrocortisone/midodrine for OH, polyethylene glycol for constipation, antimuscarinics for bladder overactivity, and levodopa dose adjustment.

Definition and Overview

Autonomic dysfunction in Parkinson's disease (PD) is a non-motor symptom affecting 70-80% of patients. It results from alpha-synuclein accumulation in autonomic ganglia and brainstem nuclei, disrupting sympathetic and parasympathetic regulation [1].

Autonomic symptoms may precede motor symptoms by years (particularly constipation and REM sleep behavior disorder) and significantly impact quality of life.

Manifestations

  • Orthostatic hypotension (30-40%): worsened by dopaminergic medications
  • Constipation (60-80%): may precede motor symptoms by 10-20 years
  • Urinary dysfunction (40-70%): nocturia, frequency, urgency
  • Sweating disorders: hyperhidrosis or hypohidrosis
  • Sexual dysfunction: erectile dysfunction in 60-70% of men
  • Sialorrhea: excessive drooling from reduced swallowing frequency

Diagnosis

MIBG myocardial scintigraphy shows reduced cardiac uptake in PD (denervated sympathetic cardiac neurons), distinguishing PD from MSA where uptake may be preserved [2].

HRV analysis reveals reduced overall variability. Tilt table testing documents orthostatic hypotension. SCOPA-AUT questionnaire screens for autonomic symptom burden [3].

Treatment

Orthostatic hypotension: fludrocortisone, midodrine, droxidopa; adjust dopaminergic medications; non-pharmacological measures (fluids, salt, compression) [4].

Constipation: polyethylene glycol (first-line), dietary fiber, adequate fluids, exercise. Lubiprostone for refractory cases.

Urinary dysfunction: antimuscarinics for overactivity (with caution for cognitive effects); mirabegron as alternative.

Levodopa dose adjustment may be needed as dopaminergic therapy can worsen orthostatic hypotension [5].

Frequently Asked Questions

FAQ content is being prepared.

References

  1. [1] Goldstein DS, Sharabi Y (2009). "Neurogenic orthostatic hypotension: a pathophysiological approach." Circulation, 119: 139-146. DOI PubMed
  2. [2] Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. (2015). "MDS clinical diagnostic criteria for Parkinson's disease." Movement Disorders, 30: 1591-1601. DOI PubMed
  3. [3] Palma JA, Kaufmann H (2018). "Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies." Movement Disorders, 33: 372-390. DOI PubMed
  4. [4] Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003). "Staging of brain pathology related to sporadic Parkinson's disease." Neurobiology of Aging, 24: 197-211. DOI PubMed
  5. [5] Chaudhuri KR, Healy DG, Schapira AH (2006). "Non-motor symptoms of Parkinson's disease: diagnosis and management." The Lancet Neurology, 5: 235-245. DOI PubMed
Parkinson diseaseautonomic dysfunctionorthostatic hypotensionconstipationMIBG scanalpha-synuclein

This content is provided for medical informational purposes only and cannot replace professional medical advice. If you have symptoms, please consult a specialist.

Are you concerned about related symptoms?

Get an accurate diagnosis at OSANG Neurosurgery.